Company Profile for AlloVir
AlloVir focuses on restoring natural immunity using innovative cell therapy for patients with weakened immune systems. The company leverages proprietary technology to create allogeneic, multi-virus specific T cells aimed at tackling serious viral diseases. It is currently advancing multiple mid- and late-stage clinical trials within its product portfolio, positioning itself as a leader in the biotechnology sector.
- Advancing multiple mid- and late-stage clinical trials.
- Utilizes innovative technology for multi-virus targeting.
- None.
--(BUSINESS WIRE)--AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.
Company: |
AlloVir |
||
|
|
||
Headquarters Address: |
139 Main Street |
||
|
Suite 500 |
||
|
Cambridge, MA 02142 |
||
|
|
||
Main Telephone: |
617-433-2605 |
||
|
|
||
Website: |
|||
|
|
||
Ticker/ISIN: |
ALVR(NASDAQ)/US0198181036 |
||
|
|
||
Type of Organization: |
Public |
||
|
|
||
Industry: |
Biotechnology |
||
|
|
||
Key Executives: |
CEO: David Hallal |
||
|
CFO: Vikas Sinha |
||
|
|
||
Investor Relations |
|
||
Contact: |
Medha Chadha |
||
Phone: |
917-765-2125 |
||
Email: |
